Why is our ADC target unique?
In order for an ADC to kill a cancer cell, it is not enough for the ADC to bind a target receptor expressed at the cell surface. The ADC must be internalized, as well as processed correctly in the intracellular compartment, in order to release and thereby activate the cytotoxic compound, which will otherwise remain inactivated while bound in ADC form.
Therefore, the properties of the ADC target receptor are key to selective and efficient drug delivery.
ADCendo has its focus on professional endocytic receptors with a strong and selective expression in particular types of cancer. The mesenchymal target receptor, uPARAP, is strongly expressed especially on sarcoma and glioblastoma cells, with very limited expression in healthy adult tissue. Moreover, uPARAP is a constitutively recycling endocytic receptor that efficiently delivers its cargo directly into the endosomal/lysosomal system to efficiently mediate ADC processing and intracellular drug release in cancer cells.
We believe that by exploiting these mechanisms in our ADC design, we may potentially obtain more efficient ADC internalization, processing, and drug release, compared to more conventional targeting strategies where the target antibody must also actively mediate receptor internalization.
Read more about these concepts in our list of relevant publications.